Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis

About this update from Medmira Inc.

[{"type":"text","content":"Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against SyphilisHALIFAX, NOVA SCOTIA / ACCESS Newswire / August 26, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) - the fastest standalone screening device for syphilis in Canada.A vital point-of-care tool for healthcare professionals, Reveal® TP is a crucial advancement in expanding access to syphilis testing across Canada-particularly in the Prairie provinces, where rates of infectious and congenital syphilis are surging.The test detects syphilis antibodies from a single finger-prick blood sample, delivering results immediately that do not fade away. It is the fastest Syphilis test licensed in Canada using MedMira's proprietary Rapid Vertical Flow (RVF) Technology.Health Canada's approval of the device is based on the results of multiple clinical trials, testing a total of 1,760 individuals, in Alberta and Saskatchewan and sponsored by Dr. Sean B. Rourke, Director of REACH Nexus and a scientist at the MAP Centre for Urban Health Solutions at St. Michael's Hospital (Unity Health Toronto) with funding from the Canadian Institutes of Health Research (CIHR). One of these studies, the \"test, treat and connect\" study, was led by Dr. Stuart Skinner of the University of Saskatchewan and Nikki Williamson of the Wellness Wheel Medical Clinic in Regina-a non-profit organization providing culturally responsive HIV and sexually transmitted and blood-borne infection (STBBI) care in First Nations communities.This precise, easy-to-use test can be deployed in a range of healthcare settings, from hospitals and doctors' offices to community health clinics and non-profit community agencies. It offers an important new option in Canada for identifying syphilis cases and connecting individuals to timely treatment and care.\"We are proud to expand Canada's diagnostic toolbox with a solution that aligns with the need for speed, reliability, and scalability,\" said Hermes Chan, CEO of MedMira. \"This approval reflects our commitment to developing technologies that address urgent public health challenges while improving access to care.\"Canada has seen a dramatic rise in syphilis cases in recent years. Syphilis is a sexually transmitt...

More updates from Medmira Inc.